FM
KPTI icon

Forward Management’s Karyopharm Therapeutics KPTI Stock Holding History

Forward Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-1,439
Closed -$396K – 369
2014
Q1 		$396K Sell
1,439
-1,983
-58% -$1.01M 0.02% 246
2013
Q4 		$822K Buy
+3,422
New +$945K 0.05% 165

Other funds holding KPTI

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCMI
Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Forward Management's KPTI Position: Q2 2014 in Review

Forward Management sold out of Karyopharm Therapeutics (KPTI) in Q2 2014, closing a stake of 1,439 shares — an estimated $396K sold.

Forward Management first reported a position in KPTI in Q4 2013 and held it in 2 quarters. The position peaked at $822K in Q4 2013. 78 funds tracked by Wall St. Rank hold KPTI as of Q2 2014.

  • Forward Management reported no remaining Karyopharm Therapeutics position as of Q2 2014 after selling out during the quarter.
  • Forward Management sold 1,439 Karyopharm Therapeutics shares in Q2 2014, an estimated $396K.
  • Forward Management first reported a position in Karyopharm Therapeutics in Q4 2013 and held it in 2 quarters.
  • Forward Management's Karyopharm Therapeutics position peaked at $822K in Q4 2013.
  • 78 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2014.

Based on Forward Management's 13F filing for Q2 2014, filed 12 Aug 2014.